Skip to content
<
>

Why producers have revived the practice of Broadway stops on national tours

With shows like “The Wiz,” “Mamma Mia!” and “Beetlejuice” including Main Stem engagements in their tours, the closer integration of the road and the Rialto has been a boon for both markets.

(L-R) “The Wiz” on Broadway, 2024; “Mamma Mia!” on Broadway, 2025; “Beetlejuice” on Broadway, 2019 (Credit: Matthew Murphy; Joan Marcus; Matthew Murphy)

“Mamma Mia, here I go again” indeed. The ABBA-scored jukebox musical is back on Broadway for the first time since its original run ended 10 years ago. This time, the production bows as a limited, six-month engagement at the Winter Garden Theatre. The entire 30-person cast of this 2025 Broadway run — 25 of whom are making their Broadway debuts — performed in the 25th anniversary touring production, which has been traveling through North America since 2023.

It's relatively rare for producers to bring a title back to Broadway as a stop on a national tour, but it might be part of a newer symbiotic relationship between Broadway and the road. Last year, a vibrant revival of “The Wiz” pulled off a successful pre-Broadway tour (which after its Main Stem run continued on a second leg); and later this year, “Beetlejuice,” which has toured since 2022, is making its own 13-week Broadway visit.

“For the right show, it’s a brilliant strategy because it’s not ‘Broadway or bust’ anymore,” Sammy Lopez, a producer and a co-founder of the educational initiative the Business of Broadway, told Broadway News. Instead, Broadway is a key part of a larger market — and strategy. “It’s a smart look at the business model that's really risky on Broadway right now, and it offers another perspective that keeps the overall theater ecosystem a bit healthier.”

Introductory Offer

$1/month for 6 months

Subscribe

Already have an account? Log in